Drug & intervention
dapagliflozin 10 MG
RxCUI 1488565
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
28 shownA Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)NCT07083401 · 2025-07-05
RECRUITINGA Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)NCT07083388 · 2025-07-03
RECRUITINGUse of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer PatientsNCT07245069 · 2025-02-01
RECRUITINGA Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordNCT06642272 · 2024-10-10
RECRUITINGEffect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based ChemotherapyNCT06711185 · 2024-01-30
RECRUITINGThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant RecipientsNCT05938712 · 2023-10-24
RECRUITINGSodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF PatientsNCT06065280 · 2022-11-01
COMPLETEDSGLT2 Inhibition in HemodialysisNCT05179668 · 2022-10-01
COMPLETEDDAPAgliflozin for Renal Protection in Heart Transplant RecipientsNCT05321706 · 2022-06-08
ACTIVE_NOT_RECRUITINGEmpagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart FailureNCT05776043 · 2022-03-15
UNKNOWNEffects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac SurgeryNCT04340908 · 2021-01-01
UNKNOWNA Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney DiseaseNCT04492722 · 2020-10-01
TERMINATEDSGLT2 Inhibition in Older Obese Adults With Pre-diabetesNCT04401904 · 2020-06-25
COMPLETEDEfficacy and Safety of Dapagliflozin in Acute Heart FailureNCT04298229 · 2020-04-01
COMPLETEDValue of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical TrialNCT04304560 · 2020-03-01
UNKNOWNDapagliflozin Effect on Glucose Variability in Patients Post Bariatric SurgeryNCT07515391 · 2019-10-22
ENROLLING_BY_INVITATIONTherapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes MellitusNCT04120623 · 2019-10-01
UNKNOWNSGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 DiabetesNCT03982381 · 2019-09-05
COMPLETEDEffectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.NCT03970044 · 2019-07-02
COMPLETEDPhthalates Exposure in Type 2 Diabetic Patients and Diuretic TherapyNCT04242758 · 2019-06-04
UNKNOWNSGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney DiseaseNCT03919656 · 2019-05-12
COMPLETEDSafety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/SaxagliptinNCT03608358 · 2019-02-27
TERMINATEDMetabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin TherapyNCT03959501 · 2017-08-16
COMPLETEDAssessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial ArteryNCT02919345 · 2017-01-01
COMPLETEDStudy to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.NCT02919059 · 2016-12-13
UNKNOWNA Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKDNCT02547935 · 2015-09-21
COMPLETEDA Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 DiabetesNCT02413398 · 2015-06-15
COMPLETEDMulticenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular EventsNCT01730534 · 2013-04-25
COMPLETEDConditions being studied
Diabetes Mellitus, Type 27Heart Failure4Type 2 Diabetes Mellitus4Breast Cancer2Chronic Kidney Disease2Kidney Failure2Type 2 Diabetes2Acute Decompensated Heart Failure1Aging1Anthracycline-induced Cardiac Toxicity1Arterial Stiffness1Bariatric Surgery Candidate1Cardiac Surgery1Cardiomyopathies1Carotid Artery Diseases1Chronic Kidney Diseases1Coronary Artery Disease1Diabete Mellitus1Diabete Type 21Diabetes Mellitus1
Research locations
Leading sponsors
AstraZeneca5Boryung Pharmaceutical Co., Ltd2Damanhour University2University of Campinas, Brazil2Consano Clinical Research, LLC1Dasman Diabetes Institute1Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud1Herlev and Gentofte Hospital1Hongchang Guo1IInstituto Gallego de Medicina Vascular1Medical University of Vienna1Medical University of Warsaw1Nanjing First Hospital, Nanjing Medical University1Oslo University Hospital1The University of Hong Kong1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.